KNSA
Kiniksa Pharmaceuticals, Ltd.
Biotechnology
Market Cap$4.22B
5Y Perf.+263.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
KNSA vs CABA vs PRAX vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
CABA
Cabaletta Bio, Inc.
Biotechnology
Market Cap$409M
5Y Perf.-65.4%
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$9.63B
5Y Perf.-36.5%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.-37.6%
KNSA vs CABA vs PRAX vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KNSA | CABA | PRAX | IMVT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $4.22B | $409M | $9.63B | $5.53B |
| Revenue (TTM) | $754M | $0.00 | $-92K | $0.00 |
| Net Income (TTM) | $73M | $-168M | $-327M | $-464M |
| Gross Margin | 39.0% | — | — | — |
| Operating Margin | 12.4% | — | — | — |
| Forward P/E | 41.6x | — | — | — |
| Total Debt | $9M | $27M | $110K | $98K |
| Cash & Equiv. | $166M | $83M | $357M | $714M |
KNSA vs CABA vs PRAX vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KNSA
CABA
PRAX
IMVT
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | 100 | 363.5 | +263.5% |
| Cabaletta Bio, Inc. (CABA) | 100 | 34.6 | -65.4% |
| Praxis Precision Me… (PRAX) | 100 | 63.5 | -36.5% |
| Immunovant, Inc. (IMVT) | 100 | 62.4 | -37.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KNSA vs CABA vs PRAX vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KNSA leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Praxis Precision Medicines, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
KNSA
Kiniksa Pharmaceuticals, Ltd.
The Income Pick
KNSA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.19
- Rev growth 60.1%, EPS growth 225.0%, 3Y rev CAGR 45.5%
- 192.4% 10Y total return vs IMVT's 173.6%
- 60.1% revenue growth vs PRAX's -100.0%
Best for: income & stability and growth exposure
CABA
Cabaletta Bio, Inc.
The Specific-Use Pick
CABA plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
PRAX
Praxis Precision Medicines, Inc.
The Momentum Pick
PRAX is the #2 pick in this set and the best alternative if momentum is your priority.
- +7.7% vs IMVT's +96.1%
Best for: momentum
IMVT
Immunovant, Inc.
The Defensive Pick
IMVT is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
- Beta 1.37, current ratio 11.16x
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KNSA | 60.1% revenue growth vs PRAX's -100.0% |
| Quality / Margins | KNSA | 9.7% margin vs PRAX's 2.4% |
| Stability / Safety | KNSA | Beta 0.19 vs CABA's 2.54, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PRAX | +7.7% vs IMVT's +96.1% |
| Efficiency (ROA) | KNSA | 9.9% ROA vs CABA's -90.2%, ROIC 17.1% vs -429.6% |
KNSA vs CABA vs PRAX vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2024
Segment breakdown not available.
KNSA vs CABA vs PRAX vs IMVT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKNSALAGGINGIMVT
Who Leads Where
KNSA leads in 3 of 6 categories
PRAX leads 1 • CABA leads 0 • IMVT leads 0 • 1 tied
Explore the data ↓IMVTImmunovant, Inc.
0leads
CABACabaletta Bio, Inc.
0leads
PRAXPraxis Precision Medi…
1leads
KNSAKiniksa Pharmaceutica…
3leads
6 Total Categories
CATEGORYLEADERvs PRAXvs CABAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KNSA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KNSA5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX3/6
Risk & VolatilityBeta, volatility, and downside exposure
KNSA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KNSA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KNSA and PRAX operate at a comparable scale, with $754M and -$92,000 in trailing revenue.
| Metric | KNSAKiniksa Pharmaceu… | CABACabaletta Bio, In… | PRAXPraxis Precision … | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $754M | $0 | -$92,000 | $0 |
| EBITDAEarnings before interest/tax | $94M | -$172M | -$357M | -$487M |
| Net IncomeAfter-tax profit | $73M | -$168M | -$327M | -$464M |
| Free Cash FlowCash after capex | $164M | -$132M | -$283M | -$423M |
| Gross MarginGross profit ÷ Revenue | +39.0% | — | — | — |
| Operating MarginEBIT ÷ Revenue | +12.4% | — | — | — |
| Net MarginNet income ÷ Revenue | +9.7% | — | — | — |
| FCF MarginFCF ÷ Revenue | +21.8% | — | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +55.5% | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +145.5% | +36.9% | +2.7% | +19.7% |
KNSA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CABA and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KNSAKiniksa Pharmaceu… | CABACabaletta Bio, In… | PRAXPraxis Precision … | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $4.2B | $409M | $9.6B | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $4.1B | $353M | $9.3B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | 75.91x | -2.44x | -24.72x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | 41.56x | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 51.65x | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 6.23x | — | — | — |
| Price / BookPrice ÷ Book value/share | 7.92x | 3.65x | 8.54x | 5.83x |
| Price / FCFMarket cap ÷ FCF | 166.24x | — | — | — |
Evenly matched — CABA and PRAX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
KNSA leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
KNSA delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-122 for CABA. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CABA's 0.24x. On the Piotroski fundamental quality scale (0–9), KNSA scores 6/9 vs CABA's 1/9, reflecting solid financial health.
| Metric | KNSAKiniksa Pharmaceu… | CABACabaletta Bio, In… | PRAXPraxis Precision … | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +13.3% | -121.7% | -43.0% | -47.1% |
| ROA (TTM)Return on assets | +9.9% | -90.2% | -40.2% | -44.1% |
| ROICReturn on invested capital | +17.1% | -4.3% | -65.0% | — |
| ROCEReturn on capital employed | +14.0% | -126.2% | -49.3% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 1 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.24x | 0.00x | 0.00x |
| Net DebtTotal debt minus cash | -$156M | -$56M | -$357M | -$714M |
| Cash & Equiv.Liquid assets | $166M | $83M | $357M | $714M |
| Total DebtShort + long-term debt | $9M | $27M | $110,000 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | — |
KNSA leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KNSA five years ago would be worth $38,913 today (with dividends reinvested), compared to $4,180 for CABA. Over the past 12 months, PRAX leads with a +775.0% total return vs IMVT's +96.1%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs CABA's -30.1% — a key indicator of consistent wealth creation.
| Metric | KNSAKiniksa Pharmaceu… | CABACabaletta Bio, In… | PRAXPraxis Precision … | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +35.5% | +81.0% | +16.4% | +5.1% |
| 1-Year ReturnPast 12 months | +112.7% | +244.8% | +775.0% | +96.1% |
| 3-Year ReturnCumulative with dividends | +333.3% | -65.8% | +1976.5% | +40.9% |
| 5-Year ReturnCumulative with dividends | +289.1% | -58.2% | -20.8% | +62.4% |
| 10-Year ReturnCumulative with dividends | +192.4% | -60.0% | -20.1% | +173.6% |
| CAGR (3Y)Annualised 3-year return | +63.0% | -30.1% | +174.9% | +12.1% |
PRAX leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
KNSA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KNSA is the less volatile stock with a 0.19 beta — it tends to amplify market swings less than CABA's 2.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KNSA currently trades 97.7% from its 52-week high vs IMVT's 90.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KNSAKiniksa Pharmaceu… | CABACabaletta Bio, In… | PRAXPraxis Precision … | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.19x | 2.54x | 1.55x | 1.37x |
| 52-Week HighHighest price in past year | $58.25 | $4.23 | $356.00 | $30.09 |
| 52-Week LowLowest price in past year | $24.85 | $1.11 | $35.18 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +97.7% | +94.6% | +93.6% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 74.9 | 60.8 | 55.6 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 708K | 2.8M | 378K | 1.4M |
KNSA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: KNSA as "Buy", CABA as "Buy", PRAX as "Buy", IMVT as "Buy". Consensus price targets imply 308.2% upside for CABA (target: $16) vs 12.4% for KNSA (target: $64).
| Metric | KNSAKiniksa Pharmaceu… | CABACabaletta Bio, In… | PRAXPraxis Precision … | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $64.00 | $16.33 | $544.40 | $45.50 |
| # AnalystsCovering analysts | 11 | 12 | 16 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | +0.1% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KNSA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRAX leads in 1 (Total Returns). 1 tied.
Best OverallKiniksa Pharmaceuticals, Lt… (KNSA)Leads 3 of 6 categories
Loading custom metrics...
KNSA vs CABA vs PRAX vs IMVT: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is KNSA or CABA or PRAX or IMVT a better buy right now?
For growth investors, Kiniksa Pharmaceuticals, Ltd.
(KNSA) is the stronger pick with 60. 1% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Kiniksa Pharmaceuticals, Ltd. (KNSA) offers the better valuation at 75. 9x trailing P/E (41. 6x forward), making it the more compelling value choice. Analysts rate Kiniksa Pharmaceuticals, Ltd. (KNSA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KNSA or CABA or PRAX or IMVT?
Over the past 5 years, Kiniksa Pharmaceuticals, Ltd.
(KNSA) delivered a total return of +289. 1%, compared to -58. 2% for Cabaletta Bio, Inc. (CABA). Over 10 years, the gap is even starker: KNSA returned +192. 4% versus CABA's -60. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KNSA or CABA or PRAX or IMVT?
By beta (market sensitivity over 5 years), Kiniksa Pharmaceuticals, Ltd.
(KNSA) is the lower-risk stock at 0. 19β versus Cabaletta Bio, Inc. 's 2. 54β — meaning CABA is approximately 1224% more volatile than KNSA relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 24% for Cabaletta Bio, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KNSA or CABA or PRAX or IMVT?
By revenue growth (latest reported year), Kiniksa Pharmaceuticals, Ltd.
(KNSA) is pulling ahead at 60. 1% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Kiniksa Pharmaceuticals, Ltd. grew EPS 225. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KNSA or CABA or PRAX or IMVT?
Kiniksa Pharmaceuticals, Ltd.
(KNSA) is the more profitable company, earning 8. 7% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 8. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KNSA leads at 11. 4% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — KNSA leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is KNSA or CABA or PRAX or IMVT more undervalued right now?
Analyst consensus price targets imply the most upside for CABA: 308.
2% to $16. 33.
07Which pays a better dividend — KNSA or CABA or PRAX or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is KNSA or CABA or PRAX or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Kiniksa Pharmaceuticals, Ltd.
(KNSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 19), +192. 4% 10Y return). Cabaletta Bio, Inc. (CABA) carries a higher beta of 2. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KNSA: +192. 4%, CABA: -60. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between KNSA and CABA and PRAX and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KNSA is a small-cap high-growth stock; CABA is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.